Literature DB >> 2831254

Pharmacokinetic profile of orally administered itraconazole in human skin.

G Cauwenbergh1, H Degreef, J Heykants, R Woestenborghs, P Van Rooy, K Haeverans.   

Abstract

Itraconazole is an orally effective antifungal agent with a high affinity for tissues. The skin kinetics in human volunteers have been studied after administration of 100 and 200 mg of itraconazole daily. From day 7 onward, tissue levels in the beard region and on the back were consistently higher than the corresponding plasma levels. The levels in the palmar stratum corneum were lower than the corresponding plasma levels but persisted for 3 weeks after discontinuation of therapy. Stratum corneum levels in the beard area were still measurable 4 weeks after the end of therapy. With the 200-mg dose, sweat levels became detectable 24 hours after the first drug intake. The sweat levels were usually lower than the corresponding plasma levels and followed the same curve as the plasma levels. Sebum levels of itraconazole were 10 times as high as the corresponding peak plasma levels. Sebum levels were undetectable 14 days after discontinuation of therapy. The results indicate that oral intake of itraconazole will result in therapeutic levels in the skin and these levels vary, depending on the region of skin tested. There are at least three routes of delivery of itraconazole to the skin: (1) passive uptake by keratinocytes in the basal layer (as shown by the continued presence of the drug in the palmar stratum corneum at a moment when plasma, sebum, and sweat levels are again undetectable); (2) a less significant excretion through the sweat glands (as shown by the lower drug levels compared with the plasma levels); and (3) a massive excretion through the sebaceous glands (as shown by the sebum levels compared with the plasma levels).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831254     DOI: 10.1016/s0190-9622(88)70037-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  27 in total

Review 1.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 2.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 3.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 4.  Tinea gladiatorum: wrestling's emerging foe.

Authors:  T D Kohl; M Lisney
Journal:  Sports Med       Date:  2000-06       Impact factor: 11.136

Review 5.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 6.  Tinea capitis: epidemiology, diagnosis and management strategies.

Authors:  Albert J Pomeranz; Svapna S Sabnis
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Pharmacology of itraconazole.

Authors:  K De Beule; J Van Gestel
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 9.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

10.  Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole.

Authors:  H C Korting; M Schäfer-Korting; H Zienicke; A Georgii; M W Ollert
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.